Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenue	$ 50,974	$ 39,479	$ 93,340	$ 76,149
Cost of goods sold	21,515	15,347	35,940	25,111
Gross profit	29,459	24,132	57,400	51,038
Operating expenses:
Research and development	7,714	5,993	15,559	12,224
Clinical and regulatory affairs	4,022	3,597	7,905	7,047
Marketing and sales	28,824	19,842	56,742	39,441
General and administrative	10,210	6,850	20,156	14,139
Restructuring costs	790	0	8,114	0
Settlement costs	0	0	4,650	0
Contract termination and business acquisition expenses	1,127	0	5,905	0
Total operating expenses	52,687	36,282	119,031	72,851
Loss from operations	(23,228)	(12,150)	(61,631)	(21,813)
Other income (expense):
Interest income	48	37	110	82
Interest expense	(3,815)	(1,493)	(7,597)	(2,955)
Other income (expense), net	(556)	766	(912)	824
Change in fair value of contingent consideration related to acquisition	(100)	(100)	(100)	(200)
Change in fair value of derivative liabilities	(38,743)	0	(43,831)	0
Total other income (expense)	(43,166)	(790)	(52,330)	(2,249)
Net loss before income tax expense	(66,394)	(12,940)	(113,961)	(24,062)
Income tax expense	(443)	(61)	(546)	(153)
Net loss	(66,837)	(13,001)	(114,507)	(24,215)
Other comprehensive income (loss) foreign currency translation	1,019	84	914	(1,670)
Comprehensive loss	$ (65,818)	$ (12,917)	$ (113,593)	$ (25,885)
Basic and diluted net loss per share (in dollars per share)	$ (0.81)	$ (0.19)	$ (1.44)	$ (0.36)
Shares used in computing basic and diluted net loss per share (in shares)	82,072	67,615	79,368	67,441